Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
28th Apr 20107:00 amPRNSilence (AIM: SLN) to Release Prelim Results on April 29
21st Apr 20107:00 amPRNSilence (AIM:SLN), AstraZeneca Extend RNAi Collaboration
15th Apr 20107:00 amPRNSilence Therapeutics (AIM: SLN) Appoints New CFO
13th Apr 20107:00 amPRNSilence(AIM:SLN) Integrates Assets from Intradigm Merger
30th Mar 20107:02 amPRNResearch Update
19th Mar 20103:27 pmPRNHolding(s) in Company
1st Mar 20107:00 amPRNDirectorate Change
15th Feb 20107:00 amPRNDirector/PDMR Shareholding
12th Feb 20103:28 pmPRNSenior Independent Director
12th Feb 20101:28 pmPRNNotification of Results
28th Jan 20103:00 pmPRNTotal Voting Rights
8th Jan 20101:00 pmPRNHolding(s) in Company
5th Jan 20101:35 pmPRNAcquisition and Issue of Equity
4th Jan 201012:40 pmPRNEGM Statement
17th Dec 200912:05 pmPRNStatement re Posting of Document
16th Dec 20095:03 pmRNSSchedule 1 - Silence Therapeutics plc
16th Dec 200912:00 pmRNSRestoration - Silence Therapeutics plc
16th Dec 200912:00 pmPRNAcquisition
14th Dec 200912:45 pmPRNAGM Statement
20th Nov 20097:00 amPRNNotice of AGM
15th Oct 20097:05 amPRNPatent Update
2nd Oct 20094:55 pmPRNCorrection : Half-yearly Report
30th Sep 20097:00 amPRNHalf-yearly Report
29th Sep 200910:15 amPRNTemporary Suspension
29th Sep 200910:15 amRNSSuspension - Silence Therapeutics plc
17th Sep 20097:00 amPRNNotice of Results
1st Sep 20094:40 pmRNSSecond Price Monitoring Extn
1st Sep 20094:35 pmRNSPrice Monitoring Extension
28th Aug 20094:25 pmPRNHolding(s) in Company
27th Aug 20094:40 pmRNSSecond Price Monitoring Extn
27th Aug 20094:35 pmRNSPrice Monitoring Extension
27th Aug 20097:00 amPRNRe Agreement
26th Aug 200911:30 amPRNHolding(s) in Company
14th Jul 200911:30 amPRNIssue of Equity
1st Jul 20094:40 pmRNSSecond Price Monitoring Extn
1st Jul 20094:35 pmRNSPrice Monitoring Extension
24th Jun 20097:00 amPRNAnnual Financial Report
23rd Jun 20097:00 amPRNResearch Update
19th Jun 20094:35 pmRNSPrice Monitoring Extension
3rd Jun 200912:05 pmPRNStatement re Approval for Clinical Trial
22nd May 20094:40 pmRNSSecond Price Monitoring Extn
22nd May 20094:35 pmRNSPrice Monitoring Extension
12th May 20094:40 pmRNSSecond Price Monitoring Extn
12th May 20094:35 pmRNSPrice Monitoring Extension
11th May 20094:40 pmRNSSecond Price Monitoring Extn
11th May 20094:35 pmRNSPrice Monitoring Extension
7th May 20094:40 pmRNSSecond Price Monitoring Extn
7th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20094:51 pmRNSSecond Price Monitoring Extn
5th May 20094:46 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.